IP Library › Patent Application 10603505
Patent Application
App. No. 10/603,505

Methods of prognosis of prostate cancer

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/603,505
Abstract

The present invention applies classical survival analysis to genome-wide gene expression profiles of prostate cancers and preoperative prostate-specific antigen levels from prostate cancer patient, to identify prognostic markers of disease relapse that provide additional predictive value relative to prostate-specific antigen concentration. The present invention provides a method of determining prognosis of prostate cancer and predicting prostate cancer outcome of a patient. The method comprises the steps of first establishing the threshold value of at least one prognostic gene of prostate cancer. Then, the amount of the prognostic gene from a prostate tissue of a prostate cancer patient is determined. The amount of the prognostic gene present in that patient is compared with the established threshold value of the prognostic gene, whereby the prognostic outcome of the patient is determined.

Claims (16)

1 . A method of determining prognosis of prostate cancer from a patient, comprising the steps of:

establishing the threshold value of at least one prognostic gene selected from the group of Table 1A, 1B and 1C,

determining the amount of said prognostic gene from a prostate tissue of a patient,

comparing the amount of said prognostic gene with the established threshold value of said prognostic gene, and

determining the prognostic outcome of the patient.

2 . The method according to claim 1 , wherein said prognostic gene is trp-p8.

3 . The method according to claim 1 , wherein the amount of said prognostic gene is determined after amplification of said prognostic gene.

4 . The method according to claim 1 , further comprising determining prostate-specific antigen.

5 . The method of claim 1 , wherein said prognosis is determined after a selected therapeutic treatment.

6 . The method according to claim 1 , wherein said prognosis contributes to selection of a therapeutic strategy.

7 . The method according to claim 1 , wherein said prognosis contributes to selection of a therapeutic strategy.

8 . A method of determining prognosis of prostate cancer from a patient, comprising the steps of:

establishing the threshold value of at least one prognostic gene selected from the group of Table 2,

determining the amount of said prognostic gene from a prostate tissue of a patient,

comparing the amount of said prognostic gene with the established threshold value of said prognostic gene, and

determining the prognostic outcome of the patient.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 28, 2006
From: SUTHERLAND, ROBERT; HENSHALL, SUSAN
To: GARVAN INSTITUTE OF MEDICAL RESEARCH
Reel/Frame 017228/0574 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2006
From: HILLER, JORDAN
To: EOS BIOTECHNOLOGY, INC.
Reel/Frame 017179/0708 →
MERGER Recorded Jan 18, 2006
From: EOS BIOTECHNOLOGY INC.
To: PROTEIN DESIGN LABS, INC.
Reel/Frame 017028/0873 →
CHANGE OF NAME Recorded Jan 18, 2006
From: PROTEIN DESIGN LABS, INC.
To: PDL BIOPHARMA, INC.
Reel/Frame 017028/0904 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 18, 2006
From: PDL BIOPHARMA, INC.
To: GARVAN INSTITUTE OF MEDICAL RESEARCH
Reel/Frame 017030/0287 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 13, 2006
From: GISH, KURT; MACK, DAVID; WILSON, KEITH; AFAR, DANIEL; HEVEZI, PETER
To: EOS BIOTECHNOLOGY, INC.
Reel/Frame 017016/0711 →